HQL News and Press, TeklaLife Sciences Investors From 10/03/19

Aprea Therapeutics (NASDAQ: APRE ) opens for trading after raising the size of its IPO to 5.67M shares from 5M and pricing its IPO at $15 , the mid‐point of the $14‐$16 expected range. More news on: Aprea Therapeutics, Monopar Therapeutics, ADC Therapeutics SA, Healthcare st...

For income investors, closed-end funds, or CEFs, are an attractive investment class that offers high income generally in the range of 6%-10%, broad diversification in terms of a variety of asset classes, and market matching total returns in the long term if selected carefully. However, CEF...

Today, I want to share with you what has been a successful tactic that I have used to assist in diversifying the Protected Principal Retirement Portfolio (PPRP). The inclusion of closed-end funds (CEFs) affords the opportunity to include a range of stocks that I otherwise would not be able to ...

By Stephen H. Dover, CFA, Executive Vice President, Head of Equities, Krzysztof Musialik, CFA, Research Analyst, Franklin Templeton Emerging Markets Equity, and Steve Kornfeld, CFA, Portfolio Manager, Research Analyst, Franklin Equity Group The biopharma industry has the potential to save...

In various past articles, I have discussed how healthcare can form an integral part of an investor's portfolio. This is due to the fact that it is a highly defensive industry that is resistant to change in the business cycle and yet still boasts relatively strong forward growth potential. Thes...

By Andy Acker, CFA & Luyi Guo, Ph.D., CFA & Rich Carney, CFA Last week, the Trump administration abandoned plans to overhaul drug rebates in Medicare while a federal judge ruled against listing prescription drug prices in TV ads. But U.S. drug reform is far from over, with implica...

By Stephen H. Dover, Executive Vice President, Head of Equities; Aman Gupta, Portfolio Manager, Research Analyst, Franklin Mutual Series; Brian DeChristopher, Research Analyst, Franklin Equity Group; Evan McCulloch, Portfolio Manager, Director of Equity Research, Franklin Equity Group; Krzysz...

By Andy Acker, CFA Global Life Sciences Portfolio Manager Andy Acker discusses how large-cap biopharmaceutical companies utilize M&A strategies to fill product pipelines and maintain steady cash flows. Transcript Andy Acker : Earlier this week, AbbVie ([[ABBV]])...

By Andy Acker, CFA Global Life Sciences Portfolio Manager Andy Acker discusses how large-cap biopharmaceutical companies utilize M&A strategies to fill product pipelines and maintain steady cash flows. Transcript Andy Acker : Earlier this week, AbbVie ([[ABBV]])...

By Andy Acker, CFA and Denny Fish Portfolio Managers Andy Acker and Denny Fish explore disruptive forces in healthcare and technology. Disruption is being felt across industries and geographies and proving to be a differentiator in the long-term performance of investors' portfolios. Su...